Mesocarb, also known as Sydnocarb or Sidnocarb, is a psychostimulant medication originally developed in the Soviet Union. It is a selective dopamine reuptake inhibitor (DRI) with a unique mechanism of action as a negative allosteric modulator and non-competitive inhibitor of the dopamine transporter (DAT).
Mesocarb has been used to treat psychiatric disorders, asthenia, apathy, and other conditions, and is currently under development for Parkinson’s disease and sleep disorders. It is administered orally and was marketed in Russia as 5 mg tablets under the brand name Sydnocarb.
Mesocarb has a modified amphetamine structure with a sydnone imine moiety, and its active enantiomer, armesocarb, is also being developed. The drug is not widely known or used outside of Russia and former Soviet countries.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Armesocarb, (R)-mesocarb |
|---|---|
| IUPAC Name | N-phenyl-N'-[3-[(2R)-1-phenylpropan-2-yl]oxadiazol-3-ium-5-yl]carbamimidate |
| CAS | 34262-84-5 |
| Molecular Weight | 322.4 |
| Molecular Formula | C18H18N4O2 |
| SMILES | C[C@H](CC1=CC=CC=C1)[N+]2=NOC(=C2)N=C(NC3=CC=CC=C3)[O-] |